In CML patients, the impact of treatment (Nilotinib vs. Imatinib) on neutrophils’ PTPRG expression significantly differed over time (Nilotinib: χ2 (3, 8) = 18.45, p = 0.001; Imatinib: (χ2 (3, 12) = 32.9, p = 0.001). The gene discussed is PTPRG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.